Literature DB >> 25201568

Serum thymus and activation-regulated chemokine (TARC/CCL17) levels reflect the disease activity in a patient with bullous pemphigoid.

R Nin-Asai1, Y Muro1, A Sekiya1, K Sugiura1, M Akiyama1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25201568     DOI: 10.1111/jdv.12719

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  5 in total

Review 1.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

Review 2.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

3.  IL-13 Genetic Susceptibility to Bullous Pemphigoid: A Potential Target for Treatment and a Prognostic Marker.

Authors:  Yiman Wang; Xuming Mao; Yangchun Liu; Yuyan Yang; Hongzhong Jin; Li Li
Journal:  Front Immunol       Date:  2022-01-24       Impact factor: 7.561

4.  miR-1291 Functions as a Potential Serum Biomarker for Bullous Pemphigoid.

Authors:  Li Qiu; Liming Zhang; Ruiqun Qi; Xinghua Gao; Hongduo Chen; Ting Xiao
Journal:  Dis Markers       Date:  2020-01-11       Impact factor: 3.434

Review 5.  Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.

Authors:  Tong Zhou; Bin Peng; Songmei Geng
Journal:  Front Immunol       Date:  2021-08-24       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.